series-a
Stage
2
Investors
About
Mondego Bio develops selective PTPN2 inhibitors aimed at enhancing cancer immunotherapy by improving tumor cell susceptibility to immune signaling pathways and offering an improved safety profile.
Explore Mondego Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.